We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Anacor Pharmaceuticals has announced the end-of-treatment results from a 60-patient, Phase II, open-label study of 5 percent and 7.5 percent solutions AN2690 in onychomycosis, a fungal infection of the nail and nail bed.
CytRx has announced that its lead drug candidate arimoclomol was shown to be safe and well-tolerated at all three doses tested in its Phase IIa clinical trial in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
YM BioSciences has announced that its DELEX Therapeutics division has received the results of an interim analysis on the first 67 patients from its randomized, placebo-controlled Phase IIb trial (DLXLEF-AP4) of AeroLEF for the treatment of moderate to severe acute pain in post-surgical patients.
BioDelivery Sciences International (BSDI) announced that the Research Advisory Panel of California has approved BDSI's two Phase III protocols for its flagship BEMATM Fentanyl product.
Cephalon announced it has received approval from the FDA to market Fentora (fentanyl buccal tablet) for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their persistent cancer pain.
Crucell has announced that the Ebola vaccine it is developing in partnership with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has begun a Phase I study.
Sanofi pasteur has initiated its first clinical study of a new generation of seasonal influenza vaccine produced using the PER.C6 cell-culture technology of Dutch biotechnology company Crucell.